JPM: Ionis Looks Past Kynamro To Profitability

13 Jan 2016

• By Lisa LaMotta

Despite significant progress on its late-stage programs and the promise of profitability, Ionis Pharmaceuticals Inc. can't seem to please investors who can only focus on the a failed partnership.

The biotech, which changed its name from ISIS pharmaceuticals in December due to its negative associations, made several small announcements during the J.P. Morgan Healthcare Conference – most positive, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

26 Mar 2025

• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

20 Mar 2025

• By Andrew McConaghie

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Sarepta Shares Plummet On News Of Elevidys Patient Death

18 Mar 2025

• By Joseph Haas

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

21 Feb 2025

• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.